jama_logo_0_0“The emergence of TRT as a multibillion-dollar industry without appropriate supporting data or oversight of its proper usage emphasizes the need for stricter controls as well as reassessment of approval pathways when the usage is not consistent with approved labeling. However, this [FDA] advisory committee meeting represented a remarkable convergence of many disciplines—academics, industry, regulatory scientists, expert panel, and the public—that collaboratively and effectively charted a blueprint for better controls, further study, and educational outreach to both physicians and patients for this important class of drugs. The safety of the public was well served by this process.” — Marc B. Garnick, M.D., in Journal of the American Medical Association article “Testosterone Replacement Therapy Faces FDA Scrutiny.” 


Read More Orange

HB Litigation Conferences Presents

Mass Tort Med School: A Bootcamp for Plaintiff Attorneys

Boca Raton

May 6-8, 2015